Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro

Drug Metabolism and Disposition

Volumn 31, Issue 5, 2003, Pages 580-588

  Naritomi, Yoichi ^a   Terashita, Shigeyuki ^a   Kagayama, Akira ^a   Sugiyama, Yuichi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIAZEPAM; DILTIAZEM; DRUG; ESTERASE; FABESETRON; FK 079; GLUCURONOSYLTRANSFERASE; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; PARACETAMOL; QUINOTOLAST; SULFOTRANSFERASE; TROGLITAZONE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ACETAMINOPHEN; ANIMALS; BENZODIAZEPINONES; CHROMANS; CRYOPRESERVATION; DIAZEPAM; DILTIAZEM; HEPATOCYTES; HUMANS; IMIDAZOLES; INDOLES; METABOLIC CLEARANCE RATE; PREDICTIVE VALUE OF TESTS; QUINOLIZINES; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TETRAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; ZIDOVUDINE;

ANIMALIA;

EID: 0037403950     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.5.580     Document Type: Conference Paper

References (50)

1. Ashforth EIL, Carlile DJ, Chenery R, and Houston JB (1995) Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Pharmcol Exp Ther 274:761-766.
2. Bayliss MK, Bell JA, Jenner WN, Park GR, and Wilson K (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29:253-268.
3. Blum MR, Liao SH, Good SS, and de Miranda P (1996) Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85 (Suppl 2A):189-194.
4. Carlile DJ, Stevens AJ, Ashforth EIL, Waghela D, and Houston JB (1998) In vivo clearance of ethoxycoumarin and its prediction from in vitro systems: use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 26:216-221.
5. Chesne C, Guyomard C, Fautrel A, Poullain MG, Fremond B, De Jong H, and Guillouzo A (1993) Viability and function in primary culture of adult hepatocytes from various animal species and human beings after cryopreservation. Hepatology 18:406-414.
6. Chiou WL and Barve A (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res (NY) 15:1792-1795.
7. Collins JM and Unadkat JD (1989) Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 17:1-9.
8. Coundouris JA, Grant MH, Engeset J, Petrie JC, and Hawksworth GM (1993) Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies. Xenobiotica 23:1399-1409.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
10. de Miranda P, Burnette TC, and Good SS (1990) Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab Dispos 18:315-320.
11. Diaz-Garcia JM, Oliver-Botana J, and Fos-Galve D (1992) Pharmacokinetics of diazepam in the rat: influence of a carbon tetrachloride-induced hepatic injury. J Pharm Sci 81:768-772.
12. Gazzard BG, Ford-Hutchinson AW, Smith MJ, and Williams R (1973) The binding of paracetamol to plasma proteins of man and pig. J Pharm Pharmacol 25:964-967.
13. Hedaya MA, Elmquist WF, and Sawchuk RJ (1990) Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm Res (NY) 7:411-417.
14. Hewitt NJ, Bühring KU, Dasenbrock J, Haunschild J, Ladstetter B, and Utesch D (2001) Studies comparing in vivo: in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey and human using cryopreserved hepatocytes, microsomes and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 29:1042-1050.
15. Hjelle JJ and Klaassen CD (1984) Glucuronidation and biliary excretion of acetaminophen in the rats. J Pharmcol Exp Ther 228:407-413.
16. Hoener BA (1994) Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos 15:295-304.
17. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev 29:891-922.
18. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:141-171.
19. Iwatsubo T, Hirota N, Ooie T, Suzuki H, and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
20. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
21. Katashima M, Fujimoto R, Ishibashi K, Tokuma Y, and Noda K (1993a) Pharmacokinetics of quinotolast sodium in rats, guinea pigs and dogs. Xenobiol Metab Dispos 8:505-514.
22. Katashima M, Fujimoto R, Ishibashi K, Tokuma Y, and Noda K (1993b) The protein binding of quinotolast to the serum and plasma and its distribution in the blood cells. Xenobiol Metab Dispos 8:515-520.
23. Klotz U, Antonin KH, and Bieck PR (1976) Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 199:67-73.
24. Kölle EU, Ochs HR, and Vollner KO (1983) Pharmacokinetic model of diltiazem. Arzneim-Forsch 33:972-977.
25. Koss FW, Mayer D, Hanidl H, and Kabbara T (1970) Pharmacokinetics of N-acetyl-paraaminophenol under the effect of phenylbutazone. Arzneim-Forsch 20:1218-1222.
26. Lave TH, Dupin S, Schmitt C, Chou RC, Jaeck D, and Coassolo PH (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
27. Lee YH, Lee MH, and Shim CK (1992) Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharm Res (NY) 9:1599-1606.
28. Levet-Trafit B, Gruyer MS, Marjanovic M, and Chou RC (1996) Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci 58:PL359-PL363.
29. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability and drug-drug interaction potential. Chem Biol Interact 121:7-16.
30. Lin JH and Levy G (1986) Effect of prevention of inorganic sulfate depletion on the pharmacokinetics of acetaminophen in rats. J Pharmacol Exp Ther 239:94-98.
31. Lin JH, Sugiyama Y, Awazu S, and Hanano M (1980) Kinetic studies on the deethylation of ethoxybenzamide: a comparative study with isolated hepatocytes and liver microsomes of rat. Biochem Pharmacol 29:2825-2830.
32. Luurila H, Olkkola KT, and Neuvonen PJ (1996) Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 78:117-122.
33. Mays DC, Dixon KF, Balboa A, Pawluk LJ, Bauer MR, Nawoot S, and Gerber N (1991) A nonprimate animal model applicable to zodovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. J Pharmacol Exp Ther 259:1261-1270.
34. Nakashima M, Kanamaru M, Terakawa M, and Fujiwara S (1993) Phase I study of quinotolast sodium - single-dose and multiple-dose studies. Jpn Pharmacol Ther 21:451-472.
35. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
36. Navia MA and Chaturvedi PR (1996) Design principles for orally bioavailable drugs. Drug Discov Today 1:179-189.
37. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
38. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
39. Piepho RW, Bloedow DC, Lacz JP, Runser DJ, Dimmit DC, and Browne RK (1982) Pharmacokinetics of diltiazem in selected animal species and human beings. Am J Cardiol 49:525-528.
40. Roberts MS and Rowland M (1986) Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177-181.
41. Ruegg CE, Silber PM, Mughal RA, Ismail J, Lu C, Bode DC, and Li AP (1997) Cytochrome-P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation. In Vitro Toxicol 10:217-222.
42. Sawada Y, Hanano M, Sugiyama Y, and Iga T (1985) Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 13:477-492.
43. Sonne J, Poulsen HE, Loft S, Dossing M, Vollmer-Larsen A, Simonsen K, Thyssen H, and Lundstrom K (1988) Therapeutic doses of codeine have no effect on acetaminophen clearance or metabolism. Eur J Clin Pharmacol 35:109-111.
44. Sugiyama Y. Sawada Y, Iga T, and Hanano M (1988) Xenobiotic metabolism and disposition. in Proceeding of the 2nd International ISSX Meeting (Kato R, Estabrook RW, and Cayen MN eds) pp 225-235, Taylor & Francis, London
45. Swales NJ and Utesch D (1998) Metabolic activity of fresh and cryopreserved dog hepatocyte. Xenobiotica 28:937-948.
46. Tanaka K, Sato M, Tomita Y, and Ichihara A (1978) Biochemical studies on liver functions in primary cultured hepatocytes of adult rats. I. Hormonal effects on cell viability and protein synthesis. J Biochem (Tokyo) 84:937-946.
47. Tokuda H, Miyao Y, and Hata T (1997) In vitro-in vivo scaling for FK079 pharmacokinetics. Xenobiol Metab Dispos 19 (Suppl):S273.
48. Tsui BHC, Feng JDZ, Buckley SJ, and Yeung PKF (1994) Pharmacokinetics and metabolism of diltiazem in rats following a single intra-arterial or single oral dose. Eur J Drug Metab Pharmacokinet 19:369-373.
49. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
50. Yazdanian M, Glynn SL, Wright JL, and Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res (NY) 15:1490-1494.